Non-Hodgkin Lymphoma Treatment Market to Rise at 8.4% CAGR till 2026; Driven by the Increasing Number of FDA Approvals

The global non-Hodgkin lymphoma treatment market size is projected to reach USD 12.57 billion by the end of 2026. The increasing number of clinical trials will bode well for the market in the coming years. According to a report published by Fortune Business Insights, titled “Non-Hodgkin Lymphoma Treatment Market Size, Share & Industry Analysis, By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Others), By Disease Type (B-cell Lymphoma, and T-cell Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), and Regional Forecast, 2019-2026,” the market was worth USD 6.60 billion in 2018 and will exhibit a CAGR of 8.4% during the forecast period.

Non-Hodgkin lymphoma is a rare form of cancer that is associated with the white blood cells in the human body. Since the white blood cells (WBCs) have a direct impact on the immunity of the body, this disease possesses severe side effects. It has the potential to reduce the total life of the human body. Due to the severe adverse effects of the disease, there is a massive emphasis on the treatment of the disease. The increasing investment in the research and development of treatment of the disease will have a positive impact on the growth of the market in the coming years. The increasing number of clinical trials will bode well for the market in the foreseeable future.

Increasing Biosimilar Products for treatment Will Provide Impetus to Market Growth

Due to the severity of the disease, several companies are investing the research and development of newer drugs and therapies associated with its treatment.  The increasing clinical trials have yielded several biosimilars in recent years. In March 2020, Teva and Celltrion announced the launch of their fourth trastuzumab biosimilar. The companies announced the introduction of ‘Herzuma,’ a product used for treatment in patients with indications of CD-20 positive. The companies stated that the product can either be used as monotherapy or in combination during chemotherapy. This latest product will not just help the company grow but will have a positive impact on the growth of the market in the coming years.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/non-hodgkin-lymphoma-treatment-market-102642

Increasing Prevalence of the Disease Will Aid Growth

The report encompasses several factors that have contributed to the growth of the market in recent years. Among all factors, the increasing prevalence of non-Hodgkin lymphoma has had the highest impact on the growth of the market. The high incidence of this disease has created a subsequent emphasis on the development of efficient treatment options. Moreover, the severity of the diseases has derived huge investments from companies across the world. The aforementioned factors will bode well for the market in the coming years.

Major Companies are Focused on Providing Efficient Products

The presence of several large scale companies will aid the growth of the market of non-Hodgkin lymphoma treatment, in the coming years. Major companies are focused on introducing newer products and drugs associated with the disease. The increasing demand for efficient treatment products have emerged in favor of the companies operating in the market. Some of the leading companies that are operating in the market include:

• Takeda Pharmaceutical Company Limited
• AstraZeneca
• Bayer AG
• Novartis AG
• Kite Pharma, Inc. / Gilead Sciences, Inc.
• Spectrum Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• Bristol Myers Squibb Company
• Janssen Pharmaceuticals, Inc.
•  Genentech, Inc. (F. Hoffmann-La Roche Ltd)
• CELGENE CORPORATION (Bristol Myers Squibb Company)s
•  Merck & Co., Inc.
• Kyowa Kirin Co., Ltd.
• AbbVie Inc.
• Sanofi
• Others

Industry Developments:

• October 2017: The U.S. FDA announced the approval of AstraZeneca’s Calquence (acalabrutinib) for adult patients with the indication of previously treated mantle cell lymphoma.

The global non-Hodgkin lymphoma treatment market is segmented on the basis of: